A second honeymoon for Parkinson's disease?

New England Journal of Medicine

Volumn 368, Issue 7, 2013, Pages 675-676

  Tanner, Caroline M ^a,b  

^a PARKINSON S INSTITUTE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVODOPA;

CLINICAL FEATURE; COST OF ILLNESS; DISEASE ASSOCIATION; EDITORIAL; HUMAN; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; NERVE STIMULATION; PARKINSON DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; RISK FACTOR; SUICIDE ATTEMPT; TREATMENT INDICATION; TREATMENT RESPONSE;

EID: 84873670501     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1214913     Document Type: Editorial

References (10)

1. Dorsey ER, Constantinescu R, Thompson JP, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007;68:384-6.
2. Pahwa R, Factor SA, Lyons KE, et al. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66:983-95.
3. Fox SHKR, Lim SY, Ravina B, et al. The Movement Disorder Society evidence-based medicine review update: treatments for the motor symptoms of Parkinson's disease. Mov Disord 2011;26:Suppl 3:S2-S41.
4. Deuschl G, Schupbach M, Knudsen K, et al. Stimulation of the subthalamic nucleus at an earlier disease stage of Parkinson's disease: concept and standards of the EARLYSTIM-study. Parkinsonism Relat Disord 2013;19:56-61.
5. Schuepbach WMM, Rau J, Knudsen K, et al. Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med 2013;368:610-22.
6. Van Den Eeden SK, Tanner CM, Bernstein AL, et al. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 2003;157:1015-22.
7. Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson's disease. Mov Disord 2005;20:1255-63.
8. Voon V, Krack P, Lang AE, et al. A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson's disease. Brain 2008;131:2720-8.
9. Castrioto A, Lozano AM, Poon YY, Lang AE, Fallis M, Moro E. Ten-year outcome of subthalamic stimulation in Parkinson disease: a blinded evaluation. Arch Neurol 2011;68:1550-6.
10. Weaver FM, Stroupe K, Cao L, et al. Parkinson's disease medication use and costs following deep brain stimulation. Mov Disord 2012;27:1398-403.